NCT05489523View on ClinicalTrials.gov

Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation

PHASE4RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2026

Conditions
Transthyretin Cardiac Amyloidosis
Interventions
DRUG

Tafamidis 61 MG

Tafamidis 61 mg by mouth daily for 12 months

Trial Locations (4)

10032

RECRUITING

Columbia University Medical Center, New York

44195

RECRUITING

Cleveland Clinic, Cleveland

75390

RECRUITING

UT Southwestern Medical Center, Dallas

90211

RECRUITING

Cedars-Sinai, Beverly Hills

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER